Reviewing Aytu BioScience Inc. (AYTU)’s and Unity Biotechnology Inc. (NASDAQ:UBX)’s results

This is therefore a comparing of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in Aytu BioScience Inc. (NASDAQ:AYTU) and Unity Biotechnology Inc. (NASDAQ:UBX). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aytu BioScience Inc. 2 4.35 N/A -7.14 0.00
Unity Biotechnology Inc. 10 0.00 N/A -6.43 0.00

Demonstrates Aytu BioScience Inc. and Unity Biotechnology Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Aytu BioScience Inc. 0.00% -73.8% -39.6%
Unity Biotechnology Inc. 0.00% -46.4% -42.4%

Liquidity

Aytu BioScience Inc. has a Current Ratio of 4.7 and a Quick Ratio of 4.4. Competitively, Unity Biotechnology Inc.’s Current Ratio is 13.7 and has 13.7 Quick Ratio. Unity Biotechnology Inc.’s better ability to pay short and long-term obligations than Aytu BioScience Inc.

Analyst Ratings

Aytu BioScience Inc. and Unity Biotechnology Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aytu BioScience Inc. 0 0 0 0.00
Unity Biotechnology Inc. 0 0 1 3.00

Competitively the average price target of Unity Biotechnology Inc. is $21, which is potential 147.06% upside.

Institutional & Insider Ownership

The shares of both Aytu BioScience Inc. and Unity Biotechnology Inc. are owned by institutional investors at 40.1% and 72.3% respectively. About 2.7% of Aytu BioScience Inc.’s share are owned by insiders. Competitively, 12.22% are Unity Biotechnology Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aytu BioScience Inc. -10.34% 5.06% 85.71% 122.17% -73.6% 162.49%
Unity Biotechnology Inc. 6.65% 22.53% -18.71% -21.98% -37.12% -42.8%

For the past year Aytu BioScience Inc. has 162.49% stronger performance while Unity Biotechnology Inc. has -42.8% weaker performance.

Summary

Unity Biotechnology Inc. beats on 5 of the 8 factors Aytu BioScience Inc.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.